Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.52)
# 866
Out of 5,134 analysts
217
Total ratings
47.55%
Success rate
22.21%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $7.63 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $22.95 | +22.00% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $167.98 | -10.70% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $183.30 | -16.53% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $15.99 | -12.45% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $83.91 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $11.48 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $31.11 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $36.92 | +57.10% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $32.90 | +30.70% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $66.62 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.96 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $127.76 | +21.32% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.99 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $19.28 | +81.54% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $6.20 | +109.68% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.12 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.80 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $24.64 | +37.99% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $43.69 | +14.44% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.50 | -9.09% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.56 | +618.87% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.29 | +210.08% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $41.66 | +39.22% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.28 | +85,837.50% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $4.21 | +1,800.24% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.04 | +188.46% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $4.04 | +172.28% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $8.73 | +37.46% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.65 | +1,842.20% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.20 | +525.00% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $36.92 | +441.71% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.43 | +179.72% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.09 | +1,048.33% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.63 | +8,734.36% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.80 | +122.22% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $80.48 | -51.54% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $39.63 | -62.15% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.37 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $4.50 | +3,900.00% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.63
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $22.95
Upside: +22.00%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $167.98
Upside: -10.70%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $183.30
Upside: -16.53%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $15.99
Upside: -12.45%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $83.91
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.48
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.11
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $36.92
Upside: +57.10%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $32.90
Upside: +30.70%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $66.62
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.96
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $127.76
Upside: +21.32%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.99
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $19.28
Upside: +81.54%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $6.20
Upside: +109.68%
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.80
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $24.64
Upside: +37.99%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $43.69
Upside: +14.44%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.50
Upside: -9.09%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.56
Upside: +618.87%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.29
Upside: +210.08%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $41.66
Upside: +39.22%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.28
Upside: +85,837.50%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $4.21
Upside: +1,800.24%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.04
Upside: +188.46%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $4.04
Upside: +172.28%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.73
Upside: +37.46%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.65
Upside: +1,842.20%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $3.20
Upside: +525.00%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $36.92
Upside: +441.71%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.43
Upside: +179.72%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.09
Upside: +1,048.33%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.63
Upside: +8,734.36%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.80
Upside: +122.22%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $80.48
Upside: -51.54%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $39.63
Upside: -62.15%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.37
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $4.50
Upside: +3,900.00%